Home > A. Molecular pathology > CDs > CD109
CD109
Monday 14 September 2015
WKP |
CD109 is a co-receptor of TGF-β1 and suppresses TGF-β signaling.
CD109 is a GPI-linked cell surface antigen expressed by CD34+ acute myeloid leukemia cell lines, T-cell lines, activated T lymphoblasts, endothelial cells, and activated platelets (Lin et al., 2002).
In addition, the platelet-specific Gov antigen system, implicated in refractoriness to platelet transfusion, neonatal alloimmune thrombocytopenia, and posttransfusion purpura, is carried by CD109 (Kelton et al., 1990; Lin et al., 2002).
In this study, CD109 protein expression in three subtypes of gallbladder cancer was examined by immunohistochemistry on human tissue samples and tissue microarrays.
Pathology
CD109 is specifically expressed in malignant squamous cells in squamous cell carcinomas (86.7%) and adenosquamous carcinomas (91.7%), but not in adenocarcinomas.
CD109 is a novel marker for squamous cell/adenosquamous carcinomas of the gallbladder. (26249215)
- Gallbladder cancer is the most common biliary tract malignancy with the worst overall prognosis.
- CD109 is specifically expressed in malignant squamous cells in squamous cell carcinomas (86.7%) and adenosquamous carcinomas (91.7%), but not in adenocarcinomas or normal gallbladder tissues.
- CD109 may be a potential pathology marker for gallbladder squamous cell/adenosquamous carcinomas.
Open references
CD109 is a novel marker for squamous cell/adenosquamous carcinomas of the gallbladder. Dong F, Lu C, Chen X, Guo Y, Liu J. Diagn Pathol. 2015 Aug 7;10:137. doi : 10.1186/s13000-015-0375-0 PMID: 26249215 (Free)